Skip to main content
. 2022 Jun 2;13:879452. doi: 10.3389/fimmu.2022.879452

Figure 5.

Figure 5

Immunoprofiling during and after treatment. (A) Percentages of peripheral NK cells with CD3-CD56+ before and after locoregional NK cell infusion. (B) The cytotoxic activity of PBMCs against K-562 cells at effector to a 10:1 E:T ratio. (C–E) The serum cytokine levels of IFN-γ, IL-10, and TGF-β.